# Summary

## Heart Failure

<details>
<summary>Management of acute heart failure</summary>

> O-FuN-DO

1. Sit the patient upright, with continuous monitoring of vital signs
1. Give high-flow `oxygen`
1. Ensure continuous positive airway pressure (CPAP)
1. Administer nitrates: `IV glyceryl trinitrate`, `Buccal glyceryl trinitrate`
1. Administer a loop diuretics: `Furosemide`
1. If ineffective, add inotropic agents: `Dobutamine`
1. IV `opiates` for distressed patients
1. Continue for long-term management

</details>

<details>
<summary>Drugs used in heart failure</summary>

1. Angiotensin-converting enzyme inhibitors (ACE inhibitors)
   - `Enalapril`, `Lisinopril`, `Captopril`
1. Angiotensin receptor blockers (ARB)
   - `Losartan`, `Valsartan`, `Candesartan`
1. Angiotension receptor neprilysin inhibitors (ARNI)
   - `Sacubitril + Valsartan`
1. `Amiodarone`
1. Beta-adrenoceptor antagonists (β-blockers)
   - `Bisoprolol`, `Carvedilol`, `Metoprolol`
1. Diuretics
   - Loop diuretics: `Furosemide`
   - Thiazide diuretics: `Bendroflumethiazide`
   - Mineralocorticoid receptor antagonists: `Spironolactone`, `Eplerenone`
   - SGLT2 inhibitors: `Canagliflozin`, `Empagliflozin`
1. `Digoxin`
1. Vasodilators
   - `Nitrates`, `Hydralazine`
1. `Ivabradine`

</details>

<details>
<summary>
  Four pillars used in HFrEF (heart failure with reduced ejection fraction) ejection fraction < 40% 
</summary>

> BAMS

1. `β`-blockers
   - `Bisoprolol`, `Carvedilol`, `Metoprolol`
1. `A`ngiotension receptor neprilysin inhibitors (ARNI)
   - `Sacubitril + Valsartan`
1. `M`RA (Mineralocorticoid Receptor Antagonists)
   - `Spironolactone`, `Eplerenone`
1. `S`GLT2i (Sodium-Glucose Co-Transporter 2 Inhibitors)
   - `Canagliflozin`, `Empagliflozin`, `Dapagliflozin`

</details>

## Angina Pectoris

<details>
<summary>Management of angina pectoris</summary>

> Anti-platelet + Anti-anginal

#### Anti-platelet

1. Low dose (75 mg) `aspirin` or `clopidogrel` (75 mg daily)
1. `Statin` (e.g., `atorvastatin`, `rosuvastatin`) even if serum cholesterol concentration is normal

#### Anti-anginal

- Start therapy: `Sublingual GTN` and `β-blockers`
- Add a `calcium channel antagonist` or a `long-acting nitrate` if needed
- If combination of 2 drugs fails, consider `coronary revascularisation` (PCI, CABG)

1. Nitrates
   - `Sublingual GTN`, `Oral isosorbide dinitrate`
1. Beta-blockers
   - `Bisoprolol`, `Carvedilol`, `Metoprolol`
1. Calcium channel antagonists
   - Dihydropyridine: `Nifedipine`, `Amlodipine`
   - Non-Dihydropyridine: `Verapamil`, `Diltiazem`
1. `Nicorandil` (Potassium channel activators) (_Alternative to nitrates_)
1. `Ivabradine`
1. `Ranolazine`

</details>

## Myocardial Infarction

<details>
<summary>Summary of treatment for acute coronary syndrome (ACS)</summary>

1. Immediate clinical assessment, ECG, Troponin
1. Oxygen + cardiac rhythm monitoring, `Aspirin` 300 mg PO, P2Y12 receptor antagonist (e.g., `clopidogrel`), `Metoprolol` 5-15 mg IV/50-100 mg PO, **Transfer to a specialist cardiology unit**
1. ST segment elevation ACS?
   - If _Yes_: **ST segment elevation ACS treatment**
   - If ~~No~~: **Non-ST segment elevation ACS treatment**

<details>
<summary>ST segment elevation ACS treatment</summary>

- Presenting < 12 hrs from symptom onset?
  - If ~~No~~: **Non-ST segment elevation ACS treatment**
  - If _Yes_: **Reperfusion therapy** → Is primary PCI feasible within 120 mins?
    - If _Yes_: `PCI` + `Glycoprotein IIb/IIIa receptor antagonist (GP-RA)` IV (`tirofiban`, `abciximab`) → **Maintenance in-hospital medication**
    - If ~~No~~: Eligible for thrombolysis?
      - If _Yes_: **Thrombolysis IV** (`streptokinase`, `alteplase`) + `LMW heparin` IV → Failed?
        - If _Yes_: Reperfusion?
        - If ~~No~~: **Early in-hospital coronary angiography** + consider `GP-RA` IV infusion → **Maintenance in-hospital medication**
      - If ~~No~~: Is delayed PCI possible?
        - If _Yes_: `PCI` + `GP-RA` IV → **Maintenance in-hospital medication**
        - If ~~No~~: **Non-ST segment elevation ACS treatment**

</details>

<details>
<summary>Non-ST segment elevation ACS treatment</summary>

1. `LMW heparin` SC, Consider `nitrate` IV perfusion
1. **Calculate GRACE score**
1. In-hospital death → Medium to high-risk ACS?
   - If _Yes_: **Early in-hospital coronary angiography** + consider `GP-RA` IV infusion → **Maintenance in-hospital medication**
   - If ~~No~~: Recurrent symptoms?
     - If _Yes_: **Early in-hospital coronary angiography** + consider `GP-RA` IV infusion
     - If ~~No~~: **Maintenance in-hospital medication** (`aspirin`, `clopidogrel`, `LMW heparin`, `statin`, `β-blocker` and `ACE inhibitor`)

</details>

</details>

<details>
  <summary></summary>

> `PCI` or `Thrombolysis`, then `Angina Pectoris management` + `Anti-coagulants` + `ACEI`

1. **Symptomatics**
   - Oxygen
   - IV opiates (`morphine`, `diamorphine`)
   - Anti-emetics (`metoclopramide`)
1. **Immediate Reperfusion therapy with PCI**
   - If PCI cannot be done within 120 mins, do it as soon as possible.
   - No benefit in non-ST segment elevation ACS
1. **Thrombolytic therapy**
   - Alternative for PCI
   - `streptokinase`, `alteplase`
   - Modern thrombolytic agents (`tenecteplase` (TNK) and `reteplase` (rPA))

- **Anti-platelet therapy**
  - Oral `aspirin` and `clopidogrel`
  - HMG CoA reductase enzyme inhibitors (statins) (`Atorvastatin` or `rosuvastatin`)
- **Anti-anginal therapy**
  - Nitrates: `Sublingual glyceryl trinitrate`, `glyceryl trinitrate` or `isosorbide dinitrate`
  - `β-blockers` (`atenolol` or `metoprolol`)
  - Calcium channel antagonists: `Verapamil`, `Diltiazem`, `Nifedipine` or `Amlodipine`
- **Anti-coagulant therapy**
  - IV Glycoprotein IIb/IIIa receptor antagonists (`tirofiban` and `abciximab`)
  - `Fondaparinux` or `Low-molecular-weight heparin` (`enoxaparin`)
- **ACE inhibitors**
  - Long-term treatment with ACE inhibitors (`enalapril` or `ramipril`)
- **Mineralocorticoid receptor antagonists**
  - `Eplerenone` or `spironolactone` in acute MI + HFrEF
- **Implantable defibrillators**
  - To prevent sudden cardiac death

</details>

## Hypertension

<details>
<summary>Anti-hypertensive drug combinations</summary>

1. Step 1:
   - Aged < 55 yrs → `A`
   - Aged > 55 yrs → `C`
1. Step 2: `A` + `C`
1. Step 3: `A` + `C` + `D`
1. Step 4: **Resistant hypertension** (`A` + `C` + `D` + consider `further diuretic` or `α-` or `β-blocker`; Consider seeking export advice)

> `A` - ACE inhibitor or ARB <br/>`C` - Calcium channel antagonists <br/>`D` - Thiazide-type diuretic <br/>`further diuretic` - Low dose of spironolactone or high dose of thiazide-like diuretic.

</details>

<details>
<summary>
Management Algorithm
</summary>

**1. Clinic Blood Pressure < 140/90 mmHg (Normotensive)**

- Offer to check blood pressure at least every 5 years, more often if blood pressure is close to 140/90 mmHg

**2. Clinic Blood Pressure ≥ 140/90 mmHg**

1. Offer ABPM (or HBPM if ABPM is declined or not tolerated)
1. Offer to assess cardiovascular risk and traget organ damage
   1. _If ABPM/HBPM < 135/85 mmHg_ (Normotensive):
      - ~~If evidence of traget organ damage~~: Consider alternative causes for target organ damage
      - Offer to check blood pressure regularly
   1. _If ABPM/HBPM ≥ 135/85 mmHg_ (Stage 1 hypertension)
      - ~~If target organ damage present or 10-yr cardiovascular risk > 20%~~: Offer anti-hypertensive drug treatment
      - ~~If < 40 yrs~~: Consider specialist referral
      - Offer life-style interventions
      - Offer patient education and interventions to support adherence to adherence to treatment
      - Offer annual review of care to monitor blood pressure, provide support and discuss lifestyle, symptoms and medication
   1. _If ABPM/HBPM ≥ 150/95 mmHg_ (Stage 2 hypertension)
      - Offer anti-hypertensive drug treatment
      - Offer life-style interventions
      - Offer patient education and interventions to support adherence to adherence to treatment
      - Offer annual review of care to monitor blood pressure, provide support and discuss lifestyle, symptoms and medication

**3. Clinic Blood Pressure ≥ 180/110 mmHg**

- _If accelerated hypertension [^3] or suspected phaeochromocytoma[^4]_: Refer same day for specialist care
- Otherwise, same management as **Clinic Blood Pressure ≥ 140/90 mmHg**

</details>

<details>
  <summary>Management of hypertensive urgency</summary>

> Gradual BP reduction over 24-48 hours using oral medications.

- ACE inhibitor (`Captopril`: 25-50 mg every 1-2 hours)
- Peripheral alpha-2 adrenergic agonist (`Clonidine`: 0.1-0.2 mg every hour (max 0.7 mg))
- Alpha-1 and Beta-adrenoceptor antagonists (`Labetalol`: 200-400 mg orally every 2-3 hours)

</details>

<details>
  <summary>Management of hypertensive emergency</summary>

> Rapid BP reduction with IV medications (reduce MAP by ≤25% in the first hour, then gradually over 24-48 hours).

- Nitrates (`Sodium nitroprusside`: 0.25-10 μg/kg/min)
- Calcium channel antagonists (`Nicardipine`: 5 mg/h, titrate to 15 mg/h)
- Alpha-1 and Beta-adrenoceptor antagonists (`Labetalol`: 20 mg IV, repeat or infusion 1-2 mg/min)
- Cardioselective beta-adrenoceptor antagonists (`Esmolol`: 500 μg/kg bolus, then 50-300 μg/kg/min)
- `Hydralazine`: 10-20 mg IV every 4-6 hours

</details>

## Astham

<details>
  <summary>Stepwise Approach to the Management of Asthma</summary>

- Use `short-acting β2 agonists (SABA)` as required in all stages
  - Consider moving up if SABA is used 3 doses a week or more
- Discontinue trial drugs if they are ineffective
- Maintain at optimal control with the lowest step and lowest dose of treatment
- Decreasing the dose of glucocorticoid by around 20-25% every 3 months is a resonable strategry for most patients

#### Step 1: Regular Preventer

- `Low dose inhaled glucocorticoid (ICS)`
- Higher doses may be required for smokers

#### Step 2: Initial Add-on Therapy

- Add `long-acting beta agonists (LABA)` to `low dose ICS` (fixed dose or MART)

#### Step 3: Additional Add-on Therapies

- Review the asthma in details
- Consider:
  - Increasing `ICS` to medium dose **OR**
  - Trial of `leukotriene antagonists (LTRA)` or a slow-release `theophylline`
- If no response to `LABA`, consider stopping `LABA`

#### Step 4: High-dose Therapies

- `High dose ICS`
- Consider trial of `LTRA`, `long-acting anti-muscarinic agents (LAMA)`, `theophylline` or a slow-release `oral β2-agonists`

#### Step 5: Continuous or Frequent Use of Oral Glucocorticoids

- `Oral prednisolone` (usually single daily dose in the morning)
  - `Bisphosphonates` for long-term high-dose oral glucocorticoid therapy (to reduce risk of osteoporosis)
- `Omalizumab (anti-IgE) therapy` for severe IgE-driven atopic asthma

</details>

<details>
  <summary>Management of acute exacerbation of asthma</summary>

#### 1. PEF 76% - 100% Best or Predicted

- If PEF of the patient is 76% - 100% **without nebulised therapy**,
  - Give usual inhaled bronchodilator
  - Observe for 60 mins
  - Discharge with usual treatment
- If patient got the PEF **with nebulised therapy**,
  - Wait 30 min and measure PEF

#### 2. PEF 51% - 75% Best or Predicted

- Arterial blood gas analysis
- Nebulised `salbutamol 5 mg` or `terbutaline 2.5 mg`
- High flow 60% `Oxygen`
- `Oral prednisolone 40 mg`
- Wait 30 min and measure PEF
  - If PEF > 60%,
    - Discharge
    - Continue `oral prednisolone` for 5 days
    - Start or double `ICS`
  - If PEF < 60%,
    - Admit to hospital
    - Follow PEF < 50% management

#### 3. PEF < 50% Best or Predicted

- Arterial blood gas analysis
- Nebulised `salbutamol 5 mg` or `terbutaline 2.5 mg` 6-12 times daily or as required
- High flow 60% `Oxygen`
- `Oral prednisolone 40 mg` (or `IV hydrocortisone 200 mg`)

##### More Investigations

- IV access
- Chest X-ray
- Plasma theophylline level
- Plasma K+
- Pulse oxymetry
- Repeat ABG may be necessary

##### After Admission

- Administer repeat `salbutamol 5 mg + ipratropium bromide 500 μg` by oxygen-driven nebuliser
- Consider `continuous salbutamol nebuliser 5-10 mg/hr `
- Consider `IV magnesium sulphate 1.2-2.0 g` over 20 mins or `aminophylline 5 mg/kg` loading dose over 20 mins followed by a continuous infusion at 1 mg/kg/hr
- Correct `fluid and electrolytes` (especially K+)
- `Assisted ventilation`: Endotracheal intubation and intermittent positive pressure ventilation (IPPV)

</details>

## COPD

<details>
  <summary>Management of COPD</summary>

#### Pharmacology

1. Bronchodilators
   - `Short-acting beta-agonists (SABA)`, inhaler or nebulised
   - `Long-acting beta-agonists (LABA)` and `long-acting muscarinic-antagonists (LAMA)`, single or combination, inhaler or nebulised
   - If they are not available, `Oral bronchodilator (e.g., theophylline)`
1. Combined inhaled glucocorticoids and Bronchodilators
   - Inhaled corticosteroids (ICS) inhaler
   - `LABA/LAMA/ICS` or `LABA/ICS` combination inhaler
1. Oral anti-inflammatories
   - `Oral glucocorticoids` (during exacerbation, for short-term only)
   - `Roflumilast (phosphodiesterase-4 inhibitor)`
1. Other maintenance measures
   - Pneumococcal vaccination
   - Annual influenza vaccination
   - Management of obesity, poor nutrition, depression
   - `Mucolytic agents` for sputum expectoration
1. Oxygen therapy and home ventilation
   - `Long-term domiciliary oxygen therapy (LTOT)` for COPD with severe hypoxaemia
   - Use 15-20 hours duration to maintain SaO2 > 90%

#### Surgery

1. `Bullectomy`
1. `Lung volume reduction surgery (LVRS)`: Thorascopically or bronchoscopically performed
1. `Lung transplantation`

#### Palliative Care

- `Morphine`: To relieve breathlessness
- `Benzodiazepines`: To reduce anxiety
- End-of-life management

</details>

<details>
  <summary>Management of acute exacerbation of COPD </summary>

1. **Oxygen Therapy**: `Controlled oxygen at 24% - 28%`
1. **Bronchodilators**: Nebulised `salbutamol and ipratropium`
1. **Glucocorticoids**: `Oral prednisolone` 30 mg for 5 days
1. **Antibiotics**: According to local guideline
1. **Ventilation**: `Non-invasive ventilation (NIV)` or `Invasive ventilation`
1. **Additional Therapy**
   - `Diuretics` for peripheral oedema
   - Smoking cessation
   - Good nutrition
1. **Discharge**
   - Discharge when patients are clinically stable on their usual maintenance medication

</details>

## COL

<details>
<summary>Management of COL</summary>

> Treat underlying causes and complications<br/>Prognosis: Child-Pugh Score

#### Supportive Management

- Daily calorie intake > 35 kcal/kg body weight
- Daily protein intake 1.2 - 1.5 g/kg
- A late evening snack to minimise overnight fasting
- Consider enteral feeding if oral feeding is inadequate
- Vitamin K, B1, Multivitamin, Glucose supplement

#### Treatment of Underlying Cause

1. `Cessation of alcohol`: For **alcoholic cirrhosis**
1. `Anti-viral therapy`:
   - `Tenofovir`, `Entecavir`: For **hepatitis B**
   - `Sofosbuvir`, `Grazoprevir`: For **hepatitis C**
1. `Desferrioxamine`: For **haemochromatosis**
1. `D-penicillamine`: For **Wilson's disease**
1. Stop or avoid hepatotoxic drugs, nephrotoxic drugs and sedatives

#### Treatment of Complications

- `Endoscopy` to screen for **oesophageal varices**
- `Regular surveillance` for **hepatocellular carcinoma**
- `Bone mineral density` for **osteoporosis** and **fractures**
- `Propranolol` to reduce portal pressure for prophylaxis of **variceal bleeding**
- `Diuretics (spironolactone)` or `dialysis` for **ascites**
- `Oral lactulose` to prevent constipation for **hepatice encephalopathy**
- `Terlipressin` + `Albumin infusion` for **hepato-renal syndrome**

### Surgical Treatment

- `Liver transplant` for chronic liver failure due to cirrhosis

<details>
<summary>
Indication for liver transplant
</summary>

> CAMP

1. `C`hronic Cirrhosis
1. `A`cute fulminant liver failure
1. `M`etabolic liver disease
1. `P`rimary hepatic malignancy

</details>

</details>

## Portal Hypertension

<details>
<summary>Management of variceal bleeding in portal hypertension</summary>

#### Primary Prevention of Variceal Bleeding

- `Non-selective β-blocker` (`propranolol` or `nadolol`) **OR**
- `Non-cardioselective vasodiating β-blocker` (`carvedilol`)

#### Management of Acute Variceal Bleeding

<details>
<summary>Management of acute bleeding from oseophageal varices</summary>

1. Suspected variceal haemorrhage
1. Start IV `terlipressin` and `antibiotic` prophylaxis
1. Urgent upper GI Endoscopy
1. Varices present?
   - If ~~No~~: Stop `terlipressin` (treat as for non-variceal haemorrhage)
   - If _Yes_: Endoscopic therapy (variceal banding, sclerotherapy)→ Haemostasis?
     - If _Yes_: Continue `terlipressin` to 72 hrs; Introduce `β-blocker` as secondary prophylaxis; Enter patient into `endoscopic banding programme` to obliterate varices
     - If ~~No~~: Further endoscopic therapy or Balloon tamponade or Emergency TIPSS (Transjugular Intrahepatic Portosystemic Stent Shunt)

</details>

- Source of bleeding should always be confirmed by endoscopy
- Prophylactic `broad-spectrum antibiotics` (IV `cephalosporin` or `piperacillin/tazobactam`)

##### Pharmacological Management

- Vasoconstrictor `Terlipressin` until bleeding stops, then up to 72 hours
- Alternative: `Octreotide`

##### Non-Pharmacological Management

1. **Variceal ligation ('banding')** + Prophylactic `PPI` ± Endotracheal intubation
1. **Balloon tamponade** ± Endotracheal intubation
1. **TIPSS** (Transjugular Intrahepatic Portosystemic Stent Shunt)
1. **Portosystemic shunt surgery**
1. **Oesophageal transection**

#### Secondary Prevention of Variceal Bleeding

- `β-blockers`
- Enter an `oesophageal banding programme` at 2-4-week intervals until the varices are obliterated

</details>

## Hepatic Encephalopathy

<details>
<summary>Management of hepatic encephalopathy</summary>

> Treat the underlying causes

1. `Lactulose` (15-30 mL)
   - Increase gradually until bowel movements twice daily
1. `Phosphate enemas`
   - In patients with refractory constipation or oral route is compromised
1. `Rifaximin` (550 mg twice daily)
   - Reduce recurent hepatic encephalopathy
1. `L-ornithine L-arginine` (LOLA)
   - To lower ammonia levels and improve encephalopathy
1. `Endotracheal intubation` if needed to protect airway
1. Dietary protein restriction is not recommended

</details>

## Ascites

<details>
<summary>Management of ascites</summary>

1. Restricting sodium intake
   - Low sodium diet
   - Drugs that cause sodium retention
1. Diuretics: `Spironolactone` + `Furosemide`
1. In refractory ascites:
   - `Paracentesis` + `IV colloid (human albumin solution)` for every 2-3 L of ascites drained
   - Alternative to paracentesis: `Transjugular Intrahepatic Portosystemic Stent Shunt` (TIPSS)

</details>

## Stroke

<details>
<summary>Emergency Management of Stroke Algorithm</summary>

> Stroke is a medical emergency!

1. Clinical diagnosis of stroke
1. Neuroimaging
   1. Ischaemic stroke → Eigible for urgent reperfusion therapy?
      - If _Yes_: `IV thrombolysis` and/or `Mechanical thrombectomy` → **Acute storke unit care**
      - If ~~No~~: `Aspirin` → **Acute stroke unit care**
   1. Haemorrhagic stroke
      - Reverse coagulation abnormality → Lower BP (< 140 mmHg) → **Acute stroke unit care**
1. Acute stroke unit care
1. Identify cause and plan secondary prevention

</details>

<details>
<summary>Strategies for secondary prevention of stroke/Management of risk factors</summary>

1. Ischaemic Stroke ← Single typical TIA
   - **ECG**
     - If _Sinus rhythm_: Request prolonged ECG monitoring if cortical TIAs/stroke
       - If _Sinus rhythm_:
         1. `Antiplatelet therapy` (`Aspirin` 300 mg at once, 75 mg daily or `Clopidogrel` 75 mg daily)
         1. `Lower cholesterol` with high intensity statin after checking liver function tests
         1. `Lower BP` if BP > 130/70 mmHg 1-2 weeks after onset (`Thiazide diuretic`, `ACE inhibitor`, Other agents)
         1. `Lifestyle modification` (Smoking cessation, Lower salt intake, Lower fat intake, Lower excess alcohol intake, Lose excess weight, Increase exercise)
       - If ~~Atrial fibrillation/Paroxysmal AF~~
     - If ~~Atrial fibrillation/Paroxysmal AF~~: **Thyroid function tests** and **Echocardiogram** → Consider `Rate control` & `Anti-arrhythmic`
       - If ~~contraindications~~ to anticoagulation (e.g. bleeding, falls, binge drinking, poor compliance) → `Antiplatelet Therapy` → `Lower cholesterol` → `Lower BP` → `Lifestyle modification`
       - If _no contraindications_: `Anticoagulation` direct oral anticoagulants (DOACs); `Warfarin` with target INR 2-3 (or 3.5 if mechanical prosthetic valve) → `Lower cholesterol` → `Lower BP` → `Lifestyle modification`
   - **Carotid duplex** → Refer if > 50% stenosis on symptomatic side → **Carotid endarterectomy** (surgery) → `Antiplatelet Therapy` → `Lower cholesterol` → `Lower BP` → `Lifestyle modification`
1. Haemorrhagic Stroke → `Lower BP` → `Lifestyle modification`

</details>

## Status Epilepticus

<details>
<summary>Emergency management of status epilepticus</summary>

> Status epilepticus is a medical emergency!

#### Initial (within 30 min)

1. Airway: Clear airway
1. Breathing: Give oxygen
1. Circulation:
   - Check vital signs
   - IV access & ECG monitoring
   - Send blood to investigate precipitating causes & analysis
1. If seizures > 5 mins:
   - Give `Midazolam` 10 mg buccally or nasally **OR**
   - `Lorazepam` 4 mg IV **OR**
   - `Diazepam` 10 mg rectally or IV
1. Repeat **once** only after 15 mins
1. Correct any metabolic trigger (e.g. hypoglycaemia, thiamine deficiency)

#### Ongoing (after 30 min)

1. **IV infusion** with _one of_:
   - `Levetiracetam`: 60 mg/kg (max dose 4500 mg) over 10 minutes
   - `Phenytoin`: 15 mg/kg at 50 mg/min (with cardiac monitoring, risk of hypotension and bradycardia)
   - `Sodium valproate`: 20-30 mg/kg IV at 40 mg/min
   - `Phenobarbital`: 10 mg/kg at 100 mg/min
1. Monitor patient's conditions (neurological, cardiac, respiratory)
1. ~~Avoid `levetiracetam` in severe renal dysfunction with eGFR < 30 mL/min/1.73m2~~; Use `sodium valproate`

#### Ongoing (after 30-60 min)

1. Transfer to intensive care
   - Start treatment for refractory status with intubation, ventilation and `general anaesthesia` (`propofol` or `thiopental`)
   - EEG monitor

#### After Status Controlled

1. **Long-term anti-epileptic medication** with _one of_:
   - `Levetiracetam` 1000-1500 mg IV, oral/nasogastric tube twice daily (adjust for renal impairment and start 10-12 hours after loading dose)
   - `Sodium valproate` 10 mg/kg IV over 3-5 mins, then 800-2000 mg/day
   - `Phenytoin`: give loading dose (if not already used as above) of 15 mg/kg, infuse at < 50 mg/min, then 300 mg/day
   - `Carbamazepine` 400 mg by nasogastric tube, then 400-1200 mg/day
1. Investigate cause and treat it
1. Remove trigger factors

</details>

## Meningitis

<details>
<summary>Management of meningitis</summary>

#### Viral Meningitis [#MG]

- No specific treatment
- Self-limiting
- Recovery within days but lymphocytic pleocytosis [^1] persists in CSF

#### Bacterial Meningitis [#MG]

- Meningococcal meningitis: **around 7 days**
- Pneumococcal meningitis treatment: **10-14 days** duration
- _Listeria meningitidis_: **21 days**

<details>
<summary>Treatment of bacterial meningitis of unknown cause (based on the British Infection Association Guideline 2016)</summary>

1. Adults aged < 60 years: `Cefotaxim` or `Ceftriaxone`
1. If penicillin-resistant pneumococcal infection is suspected: **1** + (`Vancomycin` or `Rifampicin`)
1. Age > 60 and _Listeria monocytogenes_ is suspected: **1** + (`Ampicillin` or `Amoxicillin`)
1. **2** + **3** (Age > 60 + Suspected _Listeria monocytogenes_ + Penicillin-resistant pneumococcal infection): **2** + **3**
1. Clear history of anaphylaxis to β-lactams: `Chloramphenicol` + `Vancomycin` (Add `Co-trimoxazole` if age > 60)
1. Adjunctive treatment: `Dexamethasone` (To reduce hearing loss and neurological sequelae in both children and adults in high-income countries)

</details>

<details>
<summary>Chemotherapy of bacterial meningitis when the cause is known (based on the British Infection Association Guideline 2016)</summary>

| Pathogen                                         | Regimen of choice                | Alternative agents                      |
| :----------------------------------------------- | :------------------------------- | :-------------------------------------- |
| _Neisseria meningitidis_                         | `Cefotaxime` or `Ceftriaxone`    | `Benzylpenicillin` or `Chloramphenicol` |
| _Streptococcus pneumoniae_ (β-lactams sensitive) | `Cefotaxime` or `Ceftriaxone`    | `Chloramphenicol`                       |
| _Strep. pneumoniae_ (β-lactams resistant)        | Add `Vancomycin` or `Rifampicin` | `Chloramphenicol`                       |
| _Haemophilus influenzae_                         | `Cefotaxime` or `Ceftriaxone`    | `Moxifloxacin`                          |
| _Streptococcus suis_                             | `Cefotaxime` or `Ceftriaxone`    | `Chloramphenicol`                       |
| _Listeria monocytogenes_                         | `Amoxicillin`                    | `Co-trimoxazole`                        |

</details>

#### TB Meningitis [#MG]

1. Chemotherapy (Anti-TB treatment)
   1. Intensive phase (2 months): `HRZE`
   1. Continuation phase (7-10 months): `HR`
1. Glucocorticoids

</details>

## Acute Kidney Injury (AKI)

<details>
<summary>Management of acute kidney injury</summary>

1. **Assess fluid status**:
   1. If _hypovolaemic_: Optimise systemic haemodynamic status with fluid and `inotropes` if necessary
   1. If _euvolaemic_: Match fluid intake to urine output + Additional 500 mL/24hrs for insensible losses
   1. If _fluid-overloaded_: Diuretics (loop diuretics high dose); Dialysis if unsatisfactory response
1. **Treat underlying cause**
1. If _K+ > 6.5 mmol/L and ECG changes of hyperkalaemia_:
   - `Calcium gluconate` to stablise myocardium,
   - `Oral potassium exchange resin` to prevent K+ absorption **or** `IV glucose/insulin or Sodium bicarbonate` to move K+ intracelluarly
1. **Discontinue potentially nephrotoxic drugs** and reduce doses of therapeutic drugs according to level of renal function
1. Ensure **adequate nutritional support**
1. Consider PPIs to **reduce the risk of upper GI bleeding**
1. Screen for **intercurrent infections** and treat promptly if present

</details>

## Chornic Kidney Disease (CKD)

<details>
<summary>Management of chronic kidney disease</summary>

1. Monitor Renal Function (`every 6 months`)
1. Reduction of Rate of Progression
   - Anti-hypertensive therapy
   - Reduction of proteinuria (`ACE inhibitors`, `ARBs`)
1. Treatment of Complications
   - Maintenance of fluid and electrolyte balance
     1. Urea (`Prevent excessive protein comsumption`)
     1. Potassium (`Reduce daily potassium intake`; Reduce drugs that elevate potassium (`potassium-sparing diuretics`, `ACE inhibitors`/`ARBs`); Use `potassium-binding compounds` (`sodium ziconium cyclosilicate`, `patiromer`))
     1. Sodium and Water
   - Acid-base balance (`Sodium bicarbonate supplements`)
   - Renal bone disease
     - **Hyperphosphataemia**: (`Dietary restriction of foods with high phosphate content`; Use `phosphate-binding drugs` (`Calcium carbonate`, `aluminium hydroxide`, `lanthanum carbonate`) and `polymer-based phosphate binders` (`sevelamer`))
     - **Hypocalcaemia** or **Serum PTH level > twice upper limit of normal**: `Active vitamin D metabolites`
     - **Persistent hypercalcaemia (tertiary hyperparathyroidism)**: `Parathyroidectomy` (if unavailable or failed, `calcimimetic agents` (`cinacalcet`))
   - Anaemia (`Iron supplements` for IDA)
1. Treatment of Risk Factors for Cardiovascular Disease (`Life style modifications`)
1. Preparing for Renal Replacement Therapy (`haemodialysis or Peritoneal dialysis`)

</details>

## Iron Deficiency Anaemia (IDA)

<details>
<summary>Management of IDA</summary>

1. Iron Replacement Therapy
   - Oral Iron Replacement: `Ferrous sulphate` daily continued for 3-6 months
   - Parenteral Iron Therapy: `ferric isomaltose`, `ferric carboxymaltose`, `iron dextran`, `iron sucrose`
   - Blood Transufsion: `Packed red cells`
1. Treat Underlying Cause
   - For [variceal bleeding](/medicine/theory/hepatology/portal-hypertension#management)
   - For hookworm infestation: Deworming with anti-helminths

</details>

## Thalassaemia

<details>
<summary>Management of thalassaemia-major</summary>

1. For erythropoietic failure:
   - **Cure**: Allogeneic `HSCT`(Haematopoietic Stem Cell Transplantation) from HLA (Human Leucocyte Antigen)-compatible sibling
   - `Transfusion` to maintain Hb > 10 g/dL
   - `Folic acid` 5 mg daily
1. For iron overload
   - Avoid iron-rich food, Iron therapy
   - `Iron chelation therapy` (`desferrioxamine`, `desferiprone`, `deferasirox`)
1. For splenomegaly
   - `Splenectomy`

<details>
<summary>Indication for splenomegaly</summary>

1. Hypersplenism
1. Symptomatic massive splenomegaly
1. Transfusion requirement > 250 ml/kg/year of packed red cells or > 400 ml/kg/year of whole blood

- Age: > 6 year-old to prevent post-splenectomy sepsis
- Pneumococcal vaccine, meningococcal vaccine, haemophilus influenzae vaccine: 4-6 weeks prior to splenectomy and booster dose after
- Life-long `penicillin` prophylaxis
- Low dose `aspirin` for thrombosis

</details>

</details>

## Idiopathic Thrombocytopenic Purpura (ITP)

<details>
<summary>Management of ITP</summary>

### Stable Compensated ITP

- Stable compensated ITP with platelet count > 30 x 10e9/L: `No treatment` required except at times of increased bleeding risk (surgery, biopsy)

### Spontaneous Bleeding

- `First line therapy`: High dose of `glucocorticoids`[^1] (`prednisolone` 1mg/kg daily or `dexamethasone` 40 mg daily for 4 days)
- If first line therapy failed: `IV immunoglobin + glucocorticoid` therapy
- If persistent or potentially life-threatening bleeding: **ADD** `platelet transfusion`

### Relapse

- **One relapse**: Re-introduce `glucocorticoids`
- **Two relapses** or **primary refractory disease**: `Second-line therapies`
  - Thrombopoietin receptor agonists (TPO-RA) `eltrombopag` and `romiplostim`
  - Splenic tyrosine kinase inhibitor `fostamatinib`
  - Splenectomy
  - Immunosuppressants (`rituximab`, `ciclosporin`, `mycophenolate`, `tacrolimus`)

</details>

## Diabetes Mellitus

<details>
<summary>Guidelines for glucose-lowering treatment in type 2 diabetes: adapted from ADA-EASD 2020 (American Diabetes Association-European Association for the Study of Diabetes)</summary>

> First-line therapy is `metformin` and `comprehensive lifestyle` (including weight management and physical activity).

- Add new glucose-lowering agents if HbA1c is above target

#### Indicators of High-risk or Established ASCVD, CKD or HF

1. ASCVD predominates (e.g. history of myocardial infarction)
   - `GLP-1 RA` (+ `SGLT2i`)
1. HF or CKD predominates (e.g. reduced ejection fraction, reduced eGFR)
   - `SGLT2i` (+ `GLP-1 RA`)

#### No-Indicators

1. To minimise hypoglycaemia
   - `DPP-4i` (+ `SGLT2i` (+ `GLP-1 RA`))
   - `GLP-1 RA` (+ `SGLT2i` (+ `DPP-4i`))
   - `SGLT2i` (+ `DPP-4i` (+ `GLP-1 RA`))
   - _Add later generation `SU` or `basal insulin` with lower risk of hypoglycaemia_
1. To promote weight loss
   - `GLP-1 RA` with good efficacy for weight loss (+ `SGLT2i`)
   - `SGLT2i` (+ `GLP-1 RA` with good efficacy for weight loss)
   - _Add `DPP-4i` (if not on `GLP-1 RA`) before other options (e.g. SU)_
1. Low cost
   - `SU` (+ `TZD`)
   - `TZD` (+ `SU`)
   - _Insulin therapy (`basal insulin` with lowest cost)_ Or _`DPP-4i` or `SGLT2i` with lowest cost_

</details>

## Diabetes Ketoacidosis (DKA)

<details>
<summary>Management of DKA</summary>

1. Confirm diagnosis
1. Assess severity
1. `Fluid`
   - Add `10% glucose` 125 ml/hr when glucose < 14 mmol/L
   1. ~~SBP < 90 mmHg~~
      - Fluid bolus `Normal saline` 500 ml over 10-15 min
      - If SBP < 90 mmHg, Repeat
      - If SPB > 90 mmHg,
   1. _SBP > 90 mmHg_
      - 1 L `Normal saline` over 1 hr
      - Then, 1 L `Normal saline` over 2 hr
      - Then, 1 L `Normal saline` over 4 hr
      - Cautions if kidney or heart failure history present
      - Accurate fluid blanace and aim for urine output ≥ 0.5 ml/kg/hr
1. `Insulin`
   - Fixed Rate Insulin Infusion (FRII) 0.1 unit/kg/hr
   - Continue SC basal insulin analogue if normally taken
   - Assess response hourly
   - Is blood ketones falling ≥ 0.5 mmol/hr:
     - If _Yes_: Continue FRII until **DKA resolves**
     - If ~~No~~: Check infusion pump and adjust FRII
1. `Potassium`
   - Measure venous blood gas urgently; Reassess at 1 hr and 2 hourly thereafter
   - Maintain potassium 4-5 mmol/L
   - If _> 5.5 mmol/L_: No added KCL
   - If ~~< 5.5 mmol/L~~: Add 40 mmol/L KCL (premixed)

<details>
<summary>Resolution of DKA</summary>

1. Blood ketones ≤ 0.6 mmol/L AND
1. Venous pH > 7.3 AND
1. Bicarbonate > 15 mmol/L

</details>

### Ongoing Management

- After patient is biochemically stable, and can eat and drink, restore usual insulin regimen (SC injection)
- FRII should be continued for 30 min after short-acting insulin is given at a mealtime
- Review precipitating factors
  1.  Glycaemic control
  1.  Glucose monitoring
  1.  Insulin injection technique & injection sites

</details>

## Hyperglycaemic Hyperosmolar State (HHS)

<details>
<summary>Management of HHS</summary>

1. Confirm diagnosis
1. `Fluid and Potassium`
   - _Within 1 hour_:
     - 1 L `Normal saline` over 1 hr (more rapid if SBP < 90 mmHg)
   - _After 1 hour_:
     - Adjust the rate of fluids according to clinical status and osmolality
     1. **Aim for positive balance** of 2-3 L after 6 hours, 3-6 L after 12 hours
     1. Aim for `osmolality` to decrease by 3-8 mOsmol/kg/hr
     1. `Rate of fluid` should normally be 0.5-1.0 L/hr
     1. `Rate of fall of sodium` should not exceed 10 mmol/L in 24 hrs
     1. Add `10% glucose` 125 ml/hr when glucose < 14 mmol/L
     1. Adjust `KCl` to maintain 4-5 mmol/L
1. `Insulin`
   - _Within 1 hour_:
     - _IF ketonaemia_ (blood ketone > 1 mmol/L), start `FRII` 0.05 units/kg/hr _ONLY AFTER_ `Fluid`
   - _Within 1 to 6 hours_:
     _IF_ glucose is decreasing by < 5 mmol/L/hr **AND** positive fluid balance is adequate:
     - Increase `FRII` to 0.1 units/kg/hr **OR**
     - Start `FRII` with 0.05 units/kg/hr if not already started
   - _After 6 hours_:
     - Adjust `FRII` to maintain blood glucose 10-15 mmol/L and ensure ketones are clearing

</details>

## Malaria

<details>
<summary>Specific Therapy for Severe _falciparum_ malaria</summary>

- **Preferred therapy**:
  - `Artesunate` 2.4 mg/kg IV at 0, 12 and 24 hrs,
  - Then once daily for 7 days
  - Once patient can take orally, switch to 2mg/kg orally once daily, to complete a total cumulative dose of 17-18 mg/kg
- **Alternative**:
  - `Quinine` loading dose 20 mg/kg IV over 4 hrs, up to a maximum of 1.4 g
  - Then, maintenance dose of 10 mg/kg `quinine salt` given as 4-hr infusions 3 times daily for the first 48 hrs, then twice a day, up to a maximum of 700 mg per dose or until the patient can take orally
  - Add `Doxycycline` (Use `Clindamycin` in pregnancy or young child)
  - ~~Loading dose is contraindicated if `Quinine`, `Quinidine` or `Mefloquine` in previous 24 hrs~~
  - Monitor ECG
- Avoid `Mefloquine` due to ↑risk of post-malaria neurological syndrome

</details>

<details>
<summary>Mild _falciparum_ malaria</summary>

- **Preferred therapy**: `Co-artemether` (`Artemether` + `Lumefantrine`)
- **Alternative**:
  - `Quinine` + `Doxycycline` (Use `Clindamycin` in pregnancy or young child) **OR**
  - `Atovaquone-proguanil` (`Malarone`)
- **Pregnancy**:
  - `Co-artemether` but avoid in early pregnancy
  - **Alternative**: `Quinine` + `Clindamycin`
- **Other Regimens**: `Artesunate` + `Mefloquine`

</details>

<details>
<summary>Non-_falciparum_ malaria</summary>

- **Preferred therapy**: `Chloroquine` + `Primaquine`
- **Chloroquine-resistant _P. vivax_**: `Co-artemether` as for _P. falciparum_
- **Patients with mild to moderate G6PD deficiency**: `Chloroquine` + `Primaquine` weekly orally for 8 weeks

</details>

## HIV

<details>
<summary>Treatment of Common Opportunistic Infections in Adults with AIDS</summary>

| Opportunistic infection                    | Treatment                                                                                    | Alternative Treatment                                                               | Secondary Prophylaxis                 |
| :----------------------------------------- | :------------------------------------------------------------------------------------------- | :---------------------------------------------------------------------------------- | :------------------------------------ |
| _Pneumocystis jirovecii_ Pneumonia         | `Co-trimoxazole` for 21 days; Early adjunctive `prednisone` if hypoxic                       | `Clindamycin` + `Primaquine` for 21 days                                            | `Co-trimoxazole` daily                |
| Cerebral Toxoplasmosis                     | `Sulfadiazine` + `Pyrimethamine` + `Folic acid` for 6 weeks                                  | `Co-trimoxazole` for 3 months                                                       | `Co-trimoxazole` daily                |
| Cryptococcosis                             | Liposomal `amphotericin B` + `Flucytosine` for 7 days, followed by `Fluconazole` for 8 weeks | `Amphotericin B` + `Fluconazole` for 2 weeks, followed by `Fluconazole` for 8 weeks | `Fluconazole` daily                   |
| Oesophageal Candidiasis                    | `Fluconazole` for 2 weeks                                                                    | `Itraconazole` for 14-21 days                                                       | Not usually recommended               |
| Disseminated _Mycobacterium avium_ Complex | `Clarithromycin` + `Ethambutol` daily                                                        | `Azithromycin` + `Ethambutol` daily                                                 | Continue treatment for minimal 1 year |
| Herpes Simplex Ulcers                      | `Aciclovir` for 5-10 days                                                                    | `Valaciclovir` or Famciclovir for 5-10 days                                         | `Aciclovir` daily                     |
| _Cystoisospora belli_ Diarrhoea            | `Co-trimoxazole` for 10 days                                                                 | `Ciprofloxacin` for 10 days                                                         | `Co-trimoxazole` daily                |

</details>

<details>
<summary>Anti-retroviral Therapy</summary>

| Classes                                                  | Drugs                                                     |
| :------------------------------------------------------- | :-------------------------------------------------------- |
| Nucleoside reverse transcriptase inhibitors (NRTIs)      | `Abacavir`, `Emtricitabine`, `Lamivudine`, `Tenofovir`    |
| Non-nucleoside reverse transcriptase inhibitors (NNRTIs) | `Efavirenz`, `Rilpivirine` (only if viral load < 100,000) |
| Protease inhibitors (PIs)                                | `Atazanavir`, `Darunavir`, `Lopinavir`                    |
| Integrase Strand Transfer Inhibitors (INSTIs)            | `Dolutegravir`, `Bictegravir`                             |

#### Highly Active Anti-Retroviral Therapy (HAART)

1. Two NRTIs + One NNRTI
1. Two NRTIs + One PI (boosted with `Ritonavir` or `Cobicistat`)
1. Two NRTIs + One INSTI

</details>
